-
Mashup Score: 1
TPS8055 Background: Pts with transplant-ineligible NDMM require therapies which prolong survival and improve quality of life. The combination of VRd significantly improves progression-free (PFS) and overall survival compared with Rd in NDMM, and has an acceptable safety profile. Combining VRd with a monoclonal antibody (mAb) may further improve efficacy. Isatuximab (ISA) is an anti-CD38 mAb that demonstrates antitumor and immunomodulatory activities with strong potentiation when combined with V and R in MM xenograft models. Here we describe a Phase III, randomized, open-label, multicenter study (NCT03319667; IMROZ), evaluating clinical benefit of ISA plus VRd vs VRd in pts with transplant-ineligible NDMM. Methods: Approximately 440 adult pts with symptomatic MM (International Myeloma Working Group [IMWG] criteria) will be randomly assigned, according to Revised International Staging System criteria (I or II vs III vs unknown) and age ( < 70 vs ≥70 years), in a 3:2 ratio to ISA (10 mg/k
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review - PubMed - 6 day(s) ago
Long-term follow-up of multiple myeloma (MM) clinical trials are needed to assess long-term outcomes. We aimed to investigate the length of follow-up of all phase III MM clinical trials. Median follow-up duration of clinical trials of newly diagnosed MM was longer when compared to relapsed/refractor …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 32
Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic precursor condition that precedes multiple myeloma and related disorders but has also been associated with other medical conditions. Since systematic screening is not recommended, …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 60Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study - 10 day(s) ago
Introduction Multiple myeloma (MM) is a malignancy of bone marrow plasma cells, characterized by monoclonal immunoglobulins in the blood or urine and assoc
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 34Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response - 10 day(s) ago
Blood Cancer Journal – Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response
Source: www.nature.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 38A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab - 10 day(s) ago
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 48
Background: Lenalidomide/dexamethasone has been approved as a standard treatment in multiple myeloma and is applied preferentially in older patients with c
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 44
8012 Background: Early and sensitive detection of bone marrow disease and stratified patient management according to clinical risk can confer survival advantages in multiple myeloma (MM). Whole body MRI (WB MRI) and Fluorodeoxyglucose (FDG) PET/CT are included in international guidelines for imaging in patients with a suspected diagnosis of MM. However prospective studies comparing detection of MM by contemporary WB MRI as per recent MY-RADS consensus against FDG PET/CT are lacking. We report here protocol-defined endpoints from the prospective iTIMM (NCT02403102) study, comparing WB MRI and PET/CT, their relationship with serum and bone marrow estimates of disease burden, as well as molecular tumor characteristics. Methods: Patients with newly diagnosed MM or at first relapse planned to receive chemotherapy and autologous stem cell transplantation were enrolled in iTIMM. Matched baseline WB MRI and FDG PET/CT were performed and baseline clinical data including tumor genetics collected
Source: ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 48Serum free light chain level at diagnosis in myeloma cast nephropathy—a multicentre study - 10 day(s) ago
Myeloma cast nephropathy (MCN) is a common cause of severe renal impairment in multiple myeloma (MM). The level of free light chain (FLC) that causes MCN varies substantially and there is uncertainty about the threshold level that should be used to inform …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 41Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma - PubMed - 10 day(s) ago
Multiple myeloma (MM) patients frequently attain a bone marrow (BM) minimal residual disease (MRD) negativity status in response to treatment. We identified 568 patients who achieved BM MRD negativity following autologous stem cell transplantation (ASCT) and maintenance combination therapy with an i …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
@Myeloma_Doc If I have it right (looking at the trial in progress abstract where you are the first author), you probably have the inside scoop, so I trust what you say!😀 https://t.co/FYBXSBVyr0